S. Schauer

DNMT3A mutations in myeloproliferative neoplasms

L. Bullinger, K. Döhner, H. Döhner, 2011, Leukemia.

Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study.

M. Griesshammer, H. Pahl, H. Gisslinger, 2005, Haematologica.

The platelet function defect of paroxysmal nocturnal haemoglobinuria

M. Griesshammer, M. Koksch, S. Schauer, 2004, Platelets.

Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size

M. Griesshammer, M. Koksch, S. Schauer, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations

L. Bullinger, K. Döhner, H. Döhner, 2010, Haematologica.

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

K. Döhner, H. Döhner, M. Griesshammer, 2020, Leukemia.

Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364).

K. Döhner, R. Schlenk, M. Griesshammer, 2012 .

Proteasome inhibition and oxidative reactions disrupt cellular homeostasis during heme stress

P. Buehler, L. Opitz, D. Spahn, 2014, Cell Death and Differentiation.

Mutations of EZH2 In Myeloproliferative Neoplasms with Myelofibrosis: Correlation with Molecular and Clinical Data

K. Döhner, R. Schlenk, H. Döhner, 2010 .